Core Insights - BioNTech reported a net loss of €415.8 million for Q1 2025, compared to a net loss of €315.1 million in Q1 2024, indicating a significant increase in losses year-over-year [3][7][10] - Revenues for Q1 2025 were €182.8 million, a decrease from €187.6 million in the same period last year, primarily driven by COVID-19 vaccine collaboration [3][10] - The company maintains a strong financial position with €15.9 billion in cash, cash equivalents, and security investments as of March 31, 2025 [8][9] Financial Review - Revenues for Q1 2025: €182.8 million, down from €187.6 million in Q1 2024 [3] - Net loss for Q1 2025: €415.8 million, compared to €315.1 million in Q1 2024 [7] - Basic and diluted loss per share: €1.73 for Q1 2025, up from €1.31 in Q1 2024 [9] - Cost of sales increased to €83.8 million in Q1 2025 from €59.1 million in Q1 2024 [4] - R&D expenses rose to €525.6 million in Q1 2025 from €507.5 million in Q1 2024, driven by late-stage clinical studies [5] - SG&A expenses decreased to €120.6 million in Q1 2025 from €132.6 million in Q1 2024 [6] Corporate Strategy and Outlook - BioNTech is focusing on advancing its oncology pipeline, particularly the bispecific antibody candidate BNT327 and mRNA cancer immunotherapies [8][17] - The company confirmed its financial guidance for 2025, expecting revenues between €1,700 million and €2,200 million, with a similar revenue phasing to 2024 [10][11] - Planned R&D expenses for 2025 are estimated between €2,600 million and €2,800 million, with SG&A expenses projected at €650 million to €750 million [11] Clinical Development Updates - BioNTech presented multiple clinical updates for its oncology pipeline, including promising data for BNT327 in combination with antibody-drug conjugates [8][19] - Preliminary data from ongoing trials indicate anti-tumor activity and manageable safety profiles for BNT327 in various cancer indications [18][19] - The company is preparing for the 2025/2026 season variant-adapted COVID-19 vaccine [8][26] Management Changes - Ramón Zapata-Gomez has been appointed as the new CFO effective July 1, 2025, succeeding Jens Holstein [26]

Core Insights - BioNTech SE has appointed Ramón Zapata-Gomez as Chief Financial Officer (CFO) effective July 1, 2025, succeeding Jens Holstein who will retire on June 30, 2025 [1][2][3] Company Leadership Transition - Ramón Zapata will focus on aligning BioNTech's financial direction with its strategy to become a multi-product company in oncology, optimizing financial infrastructure and performance in key markets [2][3] - Jens Holstein expressed gratitude for his tenure and highlighted BioNTech's growth into a leading global biotechnology company [3] Ramón Zapata's Background - Ramón Zapata brings over 25 years of experience in the pharmaceutical and consumer goods industries, having held leadership roles at Novartis AG, Sandoz AG, and Mondelēz International [3][4] - He has a strong track record in finance functions, overseeing M&A transactions, and driving digital finance transformations [3] BioNTech Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and other serious diseases, with a diverse portfolio of oncology product candidates [5][6] - The company is leveraging its expertise in mRNA development and manufacturing capabilities to research and develop multiple mRNA vaccine candidates for infectious diseases alongside its oncology pipeline [5]

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTech (BNTX -15.40%) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading.The severe moves were likely related to a Chinese rival in the PD-1/VEGF bispecific antibody area, Akeso (AKES.F 2.96%), receiving FDA approval for a cancer drug that utilizes similar technology, as well as an ...

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (“AACR”) Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The oral and poster presentations underline both the progress of BioNTech’s advanced priority oncology programs as well as th ...

MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once r ...

BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6% higher at $102.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3% loss over the past four weeks.The sudden increase in the stock price can be attributed to the growing investor optimism about the company’s set of novel pipeline candidates being developed for treating various oncological indications and other serious diseases.This company ...

Core Insights - ITM Isotope Technologies Munich SE has elected Dr. Barbara Weber to its Supervisory Board, effective May 01, 2025, enhancing the board's expertise in advancing its radiopharmaceutical pipeline [1][2] - Dr. Weber brings over 25 years of experience in biotech and pharmaceutical industries, having held leadership roles at major companies and founded Tango Therapeutics [1][4] - The company is focused on developing its lead Phase 3 candidate, n.c.a. 177Lu-edotreotide (ITM-11), and expanding its pipeline of radiopharmaceuticals [1][3] Company Overview - ITM is a leading radiopharmaceutical biotech company dedicated to developing therapeutics and diagnostics for hard-to-treat tumors, aiming to improve patient outcomes through precision oncology [5] - The company has a broad pipeline that includes multiple Phase 3 studies, leveraging high-quality radioisotopes combined with various targeting molecules [5] Leadership and Expertise - Dr. Weber's background includes significant achievements in oncology drug development, including leading clinical studies that resulted in FDA approvals for several drugs [4] - As a physician-scientist, Dr. Weber emphasizes the potential of targeted radiopharmaceutical therapy to enhance precision oncology treatment [3]

智通财经APP讯，映恩生物-B(09606)于2025年4月7日至4月10日招股，公司拟全球发售1507.16万股股 份，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价94.6-103.2港元，每手 100股，预期股份将于2025年4月15日(星期二)开始在联交所买卖。 我们于2019年注册成立，是全球抗体偶联药物(ADC)领域的关键领跑者，致力于为癌症和自身免疫性疾 病等患者研发ADC创新药物。我们拥有自主研发的两款核心产品，即DB-1303/BNT323(一款靶向癌症 (包括子宫内膜癌(EC)及乳腺癌(BC))的HER2 ADC候选药物)及DB-1311/BNT324(一款靶向癌症(包括小细 胞肺癌(SCLC)、去势抵抗性前列腺癌(CRPC)、食管鳞状细胞癌(ESCC)及头颈部鳞状细胞癌(HNSCC))的 B7-H3 ADC候选药物)。 除核心产品外，我们还自主研发了：五款其他临床阶段ADC(即DB-1310、DB-1305/BNT325、DB- 1312/BGC9074、DB-1419及DB-2304)，在广泛适应症中具有潜力，根据Frost & Sullivan，就总体或主 ...

Shares of Moderna and Novavax dropped more than 11% and 6%, respectively, in early trading. Meanwhile, the SPDR S&P Biotech ETF slid nearly 5%. Shares of Pfizer , which has broader businesses to insulate it from damage to its vaccine portfolio, lost about 2%. The departure of Peter Marks, the Food and Drug Administration's top vaccine regulator, has raised fresh fears about whether the Trump administration will quickly approve and promote critical shots. In his position, Marks oversaw the introduction of Co ...

Group 1 - BioNTech SE is a significant player in mRNA-based cancer therapies and vaccines for virus immunization [1] - The company plans to expand its oncology pipeline by adding candidates such as FixVac, iNeST, and BNT327 by 2025 [1]